{"brief_title": "Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B", "brief_summary": "The primary objective of this clinical research study is to establish the bioequivalence of 2 treatments, rFIX and rFIX-R, when given as a 10-minute intravenous bolus infusion.", "condition": "Hemophilia B", "intervention_type": "Drug", "intervention_name": "rFIX-R", "criteria": "Inclusion Criteria: - Moderate to severe hemophilia B (FIX: C \u22642%) - Previously treated patients (PTPs) with \u2265150 documented exposure days - Age \u2265 12 years (US sites only) Exclusion Criteria: - Detectable factor IX inhibitor defined as \u22650.6 Bethesda Units for pooled plasma reported by the local laboratory (family history of inhibitors will not exclude the patient) - Patient history of factor IX inhibitor replacement therapy - Patient unable to be off factor IX replacement therapy for at least 5 days without bleeding", "gender": "All", "minimum_age": "12 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00093210.xml"}